Neurizon secures $6million R&D Tax Incentive Rebate
Filed with ASX · · 2 pages · English
• Neurizon® has secured a cash rebate of $6.0 million from the Australian Government’s Research and Development (R&D) Tax Incentive program for the 2025 financial year (FY2025), reflecting a 48.5% cash rebate on eligible R&D activities undertaken in both Australia and overseas. • This significant rebate, a non-dilutive cornerstone of Neurizon’s funding strategy, demonstrates the benefit of the Com
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Neurizon Completes Entitlement Offer
- Global Trademark Protection Secured Across Key Markets
- Regulatory and Development Update
- New Funding Secured for HEALEY ALS Platform Trial
- Equity Raising Presentation
Later from Neurizon Therapeutics
- Appendix 4C & Quarterly Update
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- Neurizon announces leadership transition
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics